Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Veliparib Plus Carboplatin in Early Stage TNBC
NCT02032277Phase 3Completed
- Sponsor
- AbbVie Inc.
- Start
- Apr 2014
- Primary completion
- Mar 2016
- Modality
- Small Molecules
- Countries
- 15
01
Overview
A Phase 3 trial of veliparib in triple-negative breast cancer (TNBC), sponsored by AbbVie Inc.. Started Apr 2014; status: completed.
02
Drugs
veliparib
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT02032277.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02032277.